N/A N=1,490 Blood Tests for Gastritis and Gastric Neoplasms
Cancer Screening Tests
Primary: Significant Blood Test Findings Correlated With Gastric Neoplasms — 9.9; 6.5 score on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=24 Current Management of Gastrointestinal Stromal Tumors (GIST) in the Region of Coquimbo
Gastrointestinal Stromal Tumors
Primary: Number of Patients Who Survived — 5 Participants
Phase 3 N=15 Prospective Randomized Trial Comparing Gastrectomy, Metastasectomy Plus Systemic Therapy Versus Systemic Therapy Alone: GYMSSA Trial
Gastric Cancer
Primary: Overall Survival in Patients With Limited Metastatic Gastric Carcinoma: Arm I — 19; 11; 11; 4 Months
N/A N=130 Staging and Outcome Depending on Surgical Treatment in Adenocarcinomas of the Oesophagogastric Junction
Esophageal Carcinoma
Primary: Overall Survival — 12; 11; 13 participants
N/A N=40 An Analysis of Presentation and Outcome Following Treatment of Pancreatic Endocrine Neoplasms
Pancreatic Endocrine Neoplasms
Primary: Nonfunctioning and Malignant Pancreatic Endocrine Neoplasms — 28; 12; 22; 18 participants
Phase 2 N=17 A Phase II Trial of STI571 in the Treatment of Metastatic Gastric Cancer
Recurrent Gastric Cancer · Stage IV Gastric Cancer
Primary: Response Rate — 0 percentage of patients responding
Phase 2 N=18 Neo-adjuvant Chemotherapy in Locally Advanced Gastric Cancer
Stage T3-4NxM0 Gastric Cancer
Primary: Number of Participants With Pathological Response — 0; 4; 8; 3 Participants
Phase 2 N=39 Chemotherapy, Surgery, and Radiation Therapy in Treating Patients With Gastric Cancer
Gastric Cancer
Primary: Grade 3 or Higher Toxicity Incidence on Step 1 — 65.8 percentage of participants
N/A N=76 Proteiomic Fingerprints of Gastric Juice
Gastric Cancer
Primary: Number of Participants With Accurate Diagnosis for Gastric Cancer — 27; 44 participants
Phase 2 N=63 Neoadjuvant and Adjuvant Imatinib Mesylate in Treating Patients With Primary or Recurrent Malignant Gastrointestinal Stromal Tumor
Gastrointestinal Stromal Tumor
Primary: Rate of Disease Progression at 2 Years — 13.8 percentage of participants
Phase 2 N=12 Bryostatin 1 and Cisplatin in Treating Patients With Metastatic or Unresectable Stomach Cancer
Stage III Gastric Cancer · Stage IV Gastric Cancer
Primary: Observed Response Rate. — 0 Percentage of Participants
Phase 2 N=21 Saracatinib in Treating Patients With Locally Advanced or Metastatic Stomach or Gastroesophageal Junction Cancer
Adenocarcinoma of the Gastroesophageal Junction · Adenocarcinoma of the Stomach · Recurrent Gastric Cancer
Primary: Objective Tumor Response (Defined as Partial [PR] or Complete Response [CR] by RECIST Criteria) — 0 participants
Phase 2 N=33 Fluorouracil, Oxaliplatin, and Leucovorin in Treating Patients With Metastatic Stomach Cancer or Gastroesophageal Junction Cancer
Gastric Cancer
Primary: Number of Patients With Each Response in "Good Risk" Genotype (Thymidylate Synthase Promoter Enhancer Region [TSER]*2/*2 or TSER*2/*3 Genotype [Low TS Expression]) — 0…
Phase 2 N=41 Bortezomib With or Without Irinotecan in Treating Patients With Cancer of the Gastroesophageal Junction or Stomach
Adenocarcinoma of the Gastroesophageal Junction · Diffuse Adenocarcinoma of the Stomach · Intestinal Adenocarcinoma of the Stomach
Primary: True Response Rate Evaluated for the Combination of Irinotecan and PS341 by Response Evaluation Criteria in Solid Tumors (RECIST) — 3; 1 participants
Phase 1 N=23 Laparoscopic Narrow Band Imaging for Detection of Occult Cancer Metastases
Gastrointestinal and Gynecologic Malignancies
Primary: Rate of Detectable Peritoneal Metastases — 0; 2 percentage of lesions
Phase 2 N=123 Durvalumab (MEDI4736) Plus Tremelimumab for Advanced Neuroendocrine Neoplasms of Gastroenteropancreatic or Lung Origin
Neuroendocrine Tumors · Neuroendocrine Neoplasm of Lung
Primary: Clinical Benefit Rate (CBR) — 0; 0; 0; 1 Participants
Phase 2 N=49 Everolimus in Treating Patients With Previously Treated Unresectable or Metastatic Esophageal Cancer or Stomach Cancer
Esophageal Cancer · Gastric Cancer
Primary: Overall Disease-control Rate in Patients With Previously Treated Unresectable or Metastatic Adenocarcinoma of the Upper Gastrointestinal Tract Treated With Everolimus…
N/A N=99,314 Screening for Stomach Diseases and Colorectal Neoplasms With the Fecal Testing
Colorectal Cancer · Stomach Disease
Primary: Incidence of Stomach Cancer — 49; 59 Participants
Phase 2 N=53 Neoplasia Detection With Methylene Blue MMX Tablets in Patients With UC Undergoing Colonoscopy
Ulcerative Colitis
Primary: Detected Intraepithelial Neoplasia — 0.2 Number of detected IN
Phase 2 N=10 Pilot Trial of CRLX101 in Treatment of Patients With Advanced or Metastatic Stomach, Gastroesophageal, or Esophageal Cancer That Cannot be Removed by Surgery
Adenocarcinoma of the Esophagus · Adenocarcinoma of the Gastroesophageal Junction · Diffuse Adenocarcinoma of the Stomach
Primary: CRLX101 (CPT) Uptake in Tumor and Nearby Normal Tissue — 9; 0; 0; 9 Participants — p=<0.01
Phase 2 N=58 Preoperative Chemo and Chemoradiotherapy for Adenocarcinoma of the Stomach and Gastroesophageal Junction (GEJ)
Stomach Cancer · Gastric Cancer
Primary: Complete Pathologic Response Rate — 14 percentage of participants
Phase 2 N=6 Everolimus and Combination Chemotherapy in Treating Patients With Metastatic Stomach or Esophageal Cancer
Adenocarcinoma of the Esophagus · Adenocarcinoma of the Gastroesophageal Junction · Diffuse Adenocarcinoma of the Stomach
Primary: Maximum Tolerated Dose (MTD) of Everolimus — 2.5 mg
N/A N=399 Nutrition in Gastroenteropancreatic Neuroendocrine Tumor
Gastroenteropancreatic Neuroendocrine Tumor
Primary: Prevalence of Malnutrition in GEP NET — 247; 152 Participants
Phase 2 N=39 Bevacizumab, Oxaliplatin, and Docetaxel in Treating Patients With Locally Advanced Unresectable or Metastatic Stomach or Gastroesophageal Junction Cancer
Esophageal Cancer · Gastric Cancer
Primary: Time to Progression — 6.6 months
Phase 2 N=19 Laparoscopic Hyperthermic Intraperitoneal Chemoperfusion (HIPEC) for Metastatic Gastric Cancer
Gastrointestinal Cancer
Primary: Overall Survival (OS) After Hyperthermic Intraperitoneal Chemotherapy — 30.2 Months
Phase 3 N=546 Chemotherapy and Radiation Therapy After Surgery in Treating Patients With Stomach or Esophageal Cancer
Esophageal Cancer · Gastric Cancer
Primary: Overall Survival — 3.6; 3.5 years
Phase 2 N=112 Rapid Gastric and Pancreas Cancer Staging Utilizing Peritoneal Lavage
Gastric Cancer · Pancreatic Cancer
Primary: Number of Study Participants With Adequate Percutaneous Lavage Specimen Collection — 70; 2; 4 Participants
Phase 2 N=59 Docetaxel, Oxaliplatin, and Fluorouracil in Treating Patients With Metastatic or Unresectable Stomach Cancer, Gastroesophageal Junction Cancer, or Other Solid Tumor
Gastric Cancer · Unspecified Adult Solid Tumor, Protocol Specific
Primary: Maximum Tolerated Dose (MTD) of Docetaxel When Given in Combination With Oxaliplatin and Fluorouracil (Phase I) — 50 mg/m2
Phase 3 N=85 Antiproliferative Effect of Octreotide in Patients With Metastasized Neuroendocrine Tumors of the Midgut
Neuroendocrine Tumors
Primary: Time to Tumor Progression Documented by Computed Tomography (CT) or Magnetic Resonance Imaging (MRI) — 14.3; 6.0 Months
N/A N=63 Gastric Outlet Obstructions Tailored Covered Stents for GOO
Gastric Outlet Obstruction
Primary: Efficiency of Stents — 1; 7 participants